Research Library — Page 123 | Reta Compare
3563 research articles. Page 123 of 143.
Articles
- Patent Landscape of Quad-Agonist GLP Drugs
- Biosimilar Quad-Agonists: Exploring Their Plausibility
- Cost-Effectiveness Analyses Expected for Quad-Agonist GLP Drugs
- Insurance Coverage Outlook for Next-Generation GLP-1 Drugs
- Anticipated Drug-Drug Interactions with Quad-Agonist GLP Drugs
- Long-Term Safety Studies Required for Quad-Agonist GLP Drugs
- Pancreatitis, Thyroid C-Cell, and Gallbladder Risks in Quad-Agonists
- Safety Considerations for Glucagon Receptor Agonism in Quad Drugs
- Safety Considerations for the Amylin Component in Quad-Agonists
- Safety Considerations for FGF21 Pathway Activation in Obesity Treatment
- Hypoglycemia Risk in Multi-Receptor Agonist Therapy
- GI Side Effects in Quad-Agonist GLP Drugs: Expectations for Improvement
- Discontinuation and Weight Regain With Next-Gen GLP Drugs
- Peptides for Type 2 Diabetes: Current Research and Community Insights
- Top Peptides Under Investigation for Type 2 Diabetes Management
- Exploring the Clinical Trial Landscape for Peptides in Type 2 Diabetes
- Anecdotal Reports on Peptide Use for Managing Type 2 Diabetes
- Understanding Peptides in Type 2 Diabetes: Mechanisms and Evidence
- Exploring Peptide Dosing Protocols for Managing Type 2 Diabetes
- Safety Considerations for Peptide Use in Type 2 Diabetes Management
- Exploring Peptide Stacks for Managing Type 2 Diabetes
- Comparing Peptide Therapy and Standard Treatments for Type 2 Diabetes
- Future Directions in Peptide Research for Type 2 Diabetes Management
- Exploring Peptide Therapies for Obesity: Research and Community Insights
- Exploring Peptides for Obesity: Approved Treatments and Anecdotal Uses